the U.S. Centers for Disease Control and Prevention
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Trump’s Ebola travel bans stir up Covid-era conflict over outbreak response
Donald Trump and the World Health Organization are teed up for another clash over infectious disease travel bans. Trump ignored the WHO’s advice, and its criticism of travel restrictions, when he closed the U.S. border to foreigners who’d recently been in China at the outset of the Covid pandemic, and he’s ignoring the U.N. agency again now, at the outset of what is already one of the worst Ebola outbreaks ever, by barring most travelers from the affected countries. Andrew Nixon, a health...
Israel-Iran strikes threaten truce. And, Ebola is spreading at an unprecedented rate
Israel-Iran strikes threaten truce. And, Ebola is spreading at an unprecedented rate Israel-Iran-Lebanon Escalation, Trump Walks Out Of Interview, Ebola Outbreak In DRC Good morning. You're reading the Up First newsletter.
The Last Evolution, by John W Campbell Jr. (1932)
The Project Gutenberg EBook of The Last Evolution, by John Wood Campbell This eBook is for the use of anyone anywhere at no cost and with almost no restrictions whatsoever. You may copy it, give it away or re-use it under the terms of the Project Gutenberg License included with this eBook or online at www.gutenberg.org
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Abstract Nuclear receptors are central regulators of metabolism1, yet therapeutic strategies that enforce continuous receptor activation frequently lead to reduced efficacy and unacceptable toxicity. Here we report a first-principles drug design strategy that aligns pharmacokinetics with physiological signalling cycles. We developed linafexor, a potent non-bile-acid agonist of the farnesoid X receptor (FXR)2; it is engineered for rapid systemic clearance, which enables pulsatile receptor...
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.